Breakthrough in Oncology: AGTC Genomics Redefines Early Cancer Diagnosis

AGTC Genomics, a leading genomic sequencing center, has made a groundbreaking stride in precision diagnostics with the development of liquid biopsy technology, earning the Malaysia Technology Excellence Award 2023.

This innovative approach holds immense promise in reshaping early cancer detection and treatment decisions.

Game-Changing Liquid Biopsy Unveiled

Traditional blood tumor markers have been criticized for their limitations in identifying early-stage cancers, causing delayed diagnoses and reduced survival rates. AGTC Genomics’ liquid biopsy method, based on deep DNA sequencing, detects circulating tumor DNA (ctDNA) in the bloodstream, offering sensitive and specific early-stage cancer detection across various organs.

Recent findings showcased at the International Congress of Pathology And Laboratory Medicine (ICPALM2023) highlighted the unmatched potential of multi-cancer early detection using this pioneering technology.

This method not only enables early detection but also plays a crucial role in diagnosis, treatment planning, reducing invasive procedures, and monitoring for cancer recurrence.

Redefined Cancer Testing

With a comprehensive sequencing of over 500 cancer-related genes, AGTC Genomics provides a unique alternative boasting higher accuracy rates than standard blood tests, a less invasive collection process, faster results, and integration with treatment planning through advanced genomic analysis techniques.

AGTC Genomics is dedicated to ensuring accessibility and affordability of this advanced precision test for Malaysians, aiming to contribute significantly to improving cancer outcomes and fostering a healthier future in the battle against cancer.

“Early detection is the cornerstone of cancer survival and treatment. Liquid biopsy is not just another diagnostic tool; it is the future of early cancer detection,” states Professor Chee-Onn Leong, CEO of AGTC Genomics.